Myasthenia gravis: measurement of anti-AChR autoantibodies using cell line TE671. 1991

R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
Department of Neuroimmunology, Max-Planck-Institute, Martinsried, Germany.

Anti-acetylcholine receptor (AChR) antibodies in myasthenia gravis (MG) can be quantitated using AChR extracted from the human rhabdomyosarcoma cell line TE671 (AChRTE671) as a practical alternative to AChR from human amputated limbs (AChRAMP). We compared the two antigen preparations using serum samples from different clinical groups of MG patients (n = 112) and various controls (n = 189). With two exceptions, both tests were positive or negative in the same patients. However, in the generalized MG group, the TE671 assay yielded significantly lower titers than the AChRAMP assay.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
April 1994, Journal of neuroimmunology,
R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
March 2012, Journal of neurology,
R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
December 1986, Acta neurologica Scandinavica,
R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
January 2021, Frontiers in immunology,
R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
July 2008, Journal of neuroimmunology,
R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
July 2020, Neuromuscular disorders : NMD,
R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
March 1999, Clinical chemistry,
R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
April 1989, Clinical and investigative medicine. Medecine clinique et experimentale,
R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
January 1984, Neurology,
R Voltz, and R Hohlfeld, and A Fateh-Moghadam, and T N Witt, and M Wick, and C Reimers, and B Siegele, and H Wekerle
June 2014, Neurology,
Copied contents to your clipboard!